Tema Etfs LLC Purchases 7,145 Shares of BridgeBio Pharma, Inc. $BBIO

Key Points

• Tema Etfs LLC increased its stake in BridgeBio Pharma by 5.0%, owning approximately $5.15 million worth of the company's stock.
• BridgeBio Pharma's shares are currently priced at $49.59 with a 52-week range between $21.72 and $51.86.
• Following recent earnings, the company reported a 4999.9% year-over-year increase in revenue, despite a loss of ($0.95) EPS that missed consensus estimates.

Tema Etfs LLC boosted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 5.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 149,117 shares of the company's stock after purchasing an additional 7,145 shares during the period. BridgeBio Pharma comprises 1.5% of Tema Etfs LLC's holdings, making the stock its 17th largest position. Tema Etfs LLC owned approximately 0.08% of BridgeBio Pharma worth $5,155,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in BridgeBio Pharma by 71.0% during the 1st quarter. GAMMA Investing LLC now owns 920 shares of the company's stock worth $32,000 after purchasing an additional 382 shares in the last quarter. Xponance Inc. increased its holdings in BridgeBio Pharma by 3.8% during the 1st quarter. Xponance Inc. now owns 10,474 shares of the company's stock worth $362,000 after purchasing an additional 385 shares in the last quarter. Mackenzie Financial Corp increased its holdings in BridgeBio Pharma by 6.6% during the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company's stock worth $261,000 after purchasing an additional 592 shares in the last quarter. CWM LLC increased its holdings in BridgeBio Pharma by 12.8% during the 1st quarter. CWM LLC now owns 5,261 shares of the company's stock worth $182,000 after purchasing an additional 598 shares in the last quarter. Finally, GF Fund Management CO. LTD. increased its holdings in BridgeBio Pharma by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 4,839 shares of the company's stock worth $167,000 after purchasing an additional 871 shares in the last quarter. Institutional investors own 99.85% of the company's stock.

Insider Buying and Selling at BridgeBio Pharma

In related news, major shareholder Global Investors Lp Viking sold 3,500,000 shares of BridgeBio Pharma stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $44.00, for a total transaction of $154,000,000.00. Following the completion of the transaction, the insider owned 18,555,375 shares in the company, valued at approximately $816,436,500. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Charles J. Homcy sold 250,000 shares of the firm's stock in a transaction that occurred on Friday, August 8th. The stock was sold at an average price of $46.05, for a total transaction of $11,512,500.00. Following the sale, the director owned 966,674 shares of the company's stock, valued at $44,515,337.70. This trade represents a 20.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,092,912 shares of company stock valued at $181,359,210 in the last three months. Corporate insiders own 18.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on BBIO. Wall Street Zen upgraded BridgeBio Pharma from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Oppenheimer raised their price objective on BridgeBio Pharma from $60.00 to $61.00 and gave the company an "outperform" rating in a report on Wednesday, August 6th. Wells Fargo & Company raised their price objective on BridgeBio Pharma from $67.00 to $76.00 and gave the company an "overweight" rating in a report on Monday, June 30th. HC Wainwright raised their price objective on BridgeBio Pharma from $56.00 to $70.00 and gave the company a "buy" rating in a report on Friday. Finally, Truist Financial began coverage on BridgeBio Pharma in a report on Monday, July 21st. They issued a "buy" rating and a $66.00 price objective for the company. Seventeen equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $62.18.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock traded down $0.81 during midday trading on Monday, reaching $51.76. 2,995,274 shares of the company's stock were exchanged, compared to its average volume of 3,040,208. BridgeBio Pharma, Inc. has a 52 week low of $21.72 and a 52 week high of $52.85. The firm has a market cap of $9.89 billion, a price-to-earnings ratio of -12.66 and a beta of 1.25. The stock's 50-day simple moving average is $46.82 and its 200 day simple moving average is $39.17.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $110.57 million during the quarter, compared to analyst estimates of $98.46 million. During the same period in the prior year, the firm earned ($0.39) EPS. The business's revenue for the quarter was up 4999.9% compared to the same quarter last year. Research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.